Immunohistochemical demonstration of gonadotropin-releasing hormone receptors in prostate carcinoma

Janos Szabó, Attila Végh, Gergo Rácz, Béla Szende

Research output: Contribution to journalArticle

6 Citations (Scopus)


The antiandrogen and gonadotropin-releasing hormone (Gn-RH) analogue treatment of prostate carcinoma is based on decreased proliferative and increased apoptotic activity of tumor cells, induced by androgen ablation. Gn-RH analogues decrease the serum level of androgens by breaking the pituitary-gonadal axis, but increasing evidence points to the direct effect of Gn-RH analogues on tumor cells. Immunohistochemical demonstration of Gn-RH receptors recently became possible. Cryostat and paraffin sections of prostate biopsy samples of 10 untreated patients with prostate carcinoma (T2-T3, Gleason score 5-8) were investigated for Gn-RH receptors (Gn-RHR) and androgen receptors, respectively, using the immunoperoxidase method. Membrane bound, focal Gn-RHR positivity was found in 5 samples. Nuclear androgen receptor positivity appeared in 7 samples. No correlation between Gn-RHR and androgen receptor positivity was found, neither receptor status and tumor-nodes- metastasis stage nor Gleason score could be related to each other. Correlation between Gn-RHR positivity and response to luteinizing hormone-releasing hormone analogue treatment will be investigated further.

Original languageEnglish
Pages (from-to)399-401
Number of pages3
JournalUrologic Oncology: Seminars and Original Investigations
Issue number6
Publication statusPublished - Nov 1 2005


  • Carcinoma
  • Gonadotropin-releasing hormone receptor
  • Immunoperoxidase
  • Prostate

ASJC Scopus subject areas

  • Oncology
  • Urology

Fingerprint Dive into the research topics of 'Immunohistochemical demonstration of gonadotropin-releasing hormone receptors in prostate carcinoma'. Together they form a unique fingerprint.

  • Cite this